Oryzon Genomics SA (ORY) fair value: what the stock is really worth
We calculate from audited financials what Oryzon Genomics SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 12, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Oryzon Genomics SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range €1.40 – €3.82 · fair‑value band €0.5440 – €1.10 · the €2.73 price screens above the €0.7310 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Follow Oryzon Genomics in your weekly email
Every Wednesday you see whether Oryzon Genomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.
Show more
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Stock analysis
Oryzon Genomics SA (ORY) currently trades at €2.73, while our model-based Fair Value estimate is €0.7310, implying the stock looks roughly 273.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 82/100, which puts the evidence level at low.
Scenario range: €0.5440 (bear) to €1.10 (bull), the price of €2.73 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Oryzon Genomics SA reported revenue of €0 in FY2025 versus €10.6M in FY2021. Reported net income was −€2.6M in FY2025.
Key figures
Market cap €236M · P/S ratio 18.7 · EPS (TTM) €−0.0300 · Net margin −20.4% · Return on equity −2.5% · Return on assets (EBIT) −5.1% · Operating margin −75.3% · Revenue (TTM) €12.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −73%, ORY screens richer than that median.
Fair Value models
Bear €0.5440Fair Value €0.7310Bull €1.10
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−48.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
’12
’13
’14
’15
’16
’18
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−37.4% (2019) → −60.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 656 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Below median
Fair Value upside−73% · Bottom 25%
Profitability
Return on assets−3% · Above median
Net margin (TTM)−20% · Below median
Operating margin (TTM)−75% · Bottom 25%
Growth and dividend
Revenue growth49% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.55× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)21.30× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oryzon Genomics SA Fair Value". https://www.fairvalue-calculator.com/stock/ORY
Frequently asked questions
Is Oryzon Genomics SA (ORY) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of €0.7310 versus a price of €2.73, about −73% upside (overvalued).
What is the fair value of ORY?
Our model-based fair value for Oryzon Genomics SA is €0.7310 (as of Jul 12, 2026), built from audited fundamentals. The current price: €2.73.
What is the quality score of ORY?
Oryzon Genomics SA has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oryzon Genomics SA (ORY)?
Our model-based price target is the fair value of €0.7310 (as of Jul 12, 2026) from 1 valuation models. Cautious scenario €0.5440, optimistic scenario €1.10. It is a calculation from audited fundamentals, not an analyst target.
What is the Oryzon Genomics SA stock forecast for 2026?
Our models put fair value at €0.7310, about −73% upside versus a price of €2.73 (overvalued). Cautious scenario €0.5440, optimistic scenario €1.10. The calculation is refreshed regularly with new filings.
What is the revenue of Oryzon Genomics SA (ORY)?
Oryzon Genomics SA reported trailing-twelve-month revenue of about €12.6M (latest available figure, as of Jul 12, 2026).
What is the intrinsic value of Oryzon Genomics SA (ORY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oryzon Genomics SA it is €0.7310 per share (as of Jul 12, 2026), against a price of €2.73. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Oryzon Genomics SA stock overvalued or undervalued in 2026?
As of Jul 12, 2026, ORY trades above its calculated fair value: price €2.73, fair value €0.7310, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORY?
No. The price is what the market pays today (€2.73); the fair value is what the company's own numbers justify (€0.7310). For Oryzon Genomics SA the two are €2.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oryzon Genomics SA worth?
The market values Oryzon Genomics SA at about €236M (market capitalisation, as of Jul 12, 2026). Per share that is €2.73; our models calculate a fair value of €0.7310 per share.
What do the bullish and bearish scenarios say about ORY?
Our models span a range for Oryzon Genomics SA: cautious scenario €0.5440, base €0.7310, optimistic €1.10 per share (as of Jul 12, 2026, price €2.73). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oryzon Genomics SA (ORY)?
Balance-sheet figures for Oryzon Genomics SA (as of Jul 12, 2026): return on equity −2.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is ORY from its 52-week high?
Oryzon Genomics SA trades at €2.73, about 28% below its 52-week high of €3.82 and 2% above the low of €2.68 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of €0.7310 is for.
Which stocks are comparable to Oryzon Genomics SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oryzon Genomics SA stock attractive at the current price?
The data as of Jul 12, 2026: price €2.73, calculated fair value €0.7310 (−73%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ORY calculated?
We run Oryzon Genomics SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.7310, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Oryzon Genomics SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oryzon Genomics SA (ORY)?
The closing price on Sep 25, 2026 was €2.73. Our model-based fair value is €0.7310, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oryzon Genomics SA right now?
The price sits above even our optimistic bull case (€1.10). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.5440 to €1.10) leaves room in how you read the outcome.
Key figures of Oryzon Genomics SA
How large is the market capitalisation of Oryzon Genomics SA (ORY)?
The market capitalisation of Oryzon Genomics SA is €236M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oryzon Genomics SA (ORY)?
The price-to-sales ratio of Oryzon Genomics SA is 18.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oryzon Genomics SA (ORY)?
Earnings per share at Oryzon Genomics SA are €−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oryzon Genomics SA (ORY)?
The net margin of Oryzon Genomics SA is −20.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oryzon Genomics SA (ORY)?
The return on equity (ROE) of Oryzon Genomics SA is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oryzon Genomics SA (ORY)?
On an EBIT basis the return on assets of Oryzon Genomics SA is −5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oryzon Genomics SA (ORY)?
The operating margin of Oryzon Genomics SA is −75.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oryzon Genomics SA (ORY)?
Revenue at Oryzon Genomics SA is growing +48.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oryzon Genomics SA (ORY)?
Earnings per share at Oryzon Genomics SA are growing −28.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Oryzon Genomics SA (ORY) generate?
The free cash flow of Oryzon Genomics SA is −€2.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oryzon Genomics SA (ORY) hold?
Oryzon Genomics SA holds more cash than debt, €16.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Oryzon Genomics SA in the live analysis
One click puts Oryzon Genomics SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
